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Objectives: Membrane-targeted application of complement inhibitors may ameliorate ischemia/reperfusion (I/R) injury by directly targeting
damaged cells. We investigated whether Mirococept, a membrane-targeted, myristoylated peptidyl construct derived from complement
receptor 1 (CR1) could attenuate I/R injury following acute myocardial infarction in pigs.
Methods: In a closed-chest pig model of acute myocardial infarction, Mirococept, the non-tailed derivative APT154, or vehicle was
administered intracoronarily into the area at risk 5 min pre-reperfusion. Infarct size, cardiac function and inflammatory status were evaluated.
Results: Mirococept targeted damaged vasculature and myocardium, significantly decreasing infarct size compared to vehicle, whereas
APT154 had no effect. Cardioprotection correlated with reduced serum troponin I and was paralleled by attenuated local myocardial
complement deposition and tissue factor expression. Myocardial apoptosis (TUNEL-positivity) was also reduced with the use of Mirococept.
Local modulation of the pro-inflammatory and pro-coagulant phenotype translated to improved left ventricular end-diastolic pressure,
ejection fraction and regional wall motion post-reperfusion.
Conclusions: Local modification of a pro-inflammatory and pro-coagulant environment after regional I/R injury by site-specific application
of a membrane-targeted complement regulatory protein may offer novel possibilities and insights into potential treatment strategies of
reperfusion-induced injury.
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Reperfusion following ischemia is known to induce a pro-
inflammatory reaction, involving activation of the classical,
alternative and lectin complement pathways [1,2]. The im-
portance of each of the three different complement pathways
may, in part, depend on the organ affected. Furthermore, the
injured organ itself up-regulates the production of comple-
ment components, which contribute to reperfusion damage
[3].
In vivo, membrane-bound regulators of complement, in-
cluding membrane cofactor protein (MCP, CD46), decay-ed by Elsevier B.V. All rights reserved.
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as complement receptor type 1 (CR1, CD35) protect against
unwanted, harmful complement activation [4]. CR1 influ-
ences the classical and alternative pathway by inhibiting the
C3/C5 convertases, acting as a cofactor for factor-I mediated
cleavage of C4b/C3b and for the subsequent cleavage of
iC3b to C3c and C3dg complement fragments [4]. Further-
more, CR1 is up-regulated on human vascular endothelial
cells following hypoxic stress and mediates immune com-
plex processing [5]. These properties render it ideal to ex-
ploit therapeutically in complement-mediated disease states.
In a soluble recombinant form, it has been used in several
studies to successfully treat I/R- and cardiopulmonary by-
pass-associated injury [6–8]. Local, directed cytoprotection
and complement inhibition with CR1, modified to bind to
(damaged) cell membranes, holds out the prospect of im-
proved efficacy through increasing the effective concentra-
tion of the complement regulatory pharmacophore at the site
where it is needed.
In this report we describe the use of Mirococept [9], an
engineered fragment of soluble (s)CR1, which, through
coupling to a reagent comprising a peptide motif and a
lipophilic tail [9,10], enables tethering of the inhibitor to cell
surfaces. We hypothesized that since pro-inflammatory com-
plement components are formed and assembled at the sur-
face of damaged cells, intracoronary infusion of Mirococept
to damaged endothelium and myocardium may reduce I/R
injury in a pig model of acute myocardial infarction.
2. Materials and methods
Care and use of animals in the present study were in
compliance with the Guide for the Care and Use of Labo-
ratory Animals (NIH publication no. 85-23, revised 1996) as
well as Swiss National guidelines.
2.1. Materials
Mirococept is a soluble, recombinant protein derived
from soluble complement receptor 1 (sCR1) modified with
membrane-binding properties through a myristoylated pep-
tide sequence. The membrane-binding moiety was designed
for posttranslational chemical attachment to the short con-
sensus repeats 1–3 [9,10] and is based on the myristoyl
electrostatic switch structural feature of intracellular proteins
[11]. Membrane localization of Mirococept is rapid (com-
plete in vitro within 2 min at 25 °C) and the dissociation half-
life averages several hours. Radiolabelling experiments sug-
gest that the modified protein is retained 5–10 times longer
than the unmodified form (see below). Further details on
construction and structure of Mirococept can be found in the
publication of Pratt et al. [12] and elsewhere [10,13,14]. The
recombinant non-tailed CR1 fragment APT154 possesses
identical chemical and complement inhibitory properties as
Mirococept, but is untagged and therefore does not contain
the membrane-binding moiety. A vehicle control was usedwhich contains all but the active Mirococept or APT154,
respectively. All substances were produced and provided
by Inflazyme (Inflazyme Pharmaceuticals Ltd., Richmond,
Canada).
2.2. Experimental model
Eighteen large white pigs (30±2 kg) were premedi-
cated with intramuscular ketamine (20 mg/kg) and xylazine
(2 mg/kg), followed by intravenous midazolam (0.5 mg/kg)
and atropine (0.05 mg/kg), intubated and mechanically
ventilated with a Draeger respirator (O2/N2O 1:3, Isoflur-
ane 1–1.5 vol.%). Central venous and arterial lines were
introduced and a single bolus of unfractionated heparin
(2500 IU) was administered intravenously. Baseline values
were recorded during a 30-minutes stabilization period.
The left anterior descending artery (LAD) was occluded
with a semi compliant over-the-wire percutaneous coronary
intervention catheter (Concerto, Occam, the Netherlands,
balloon length 10 mm, diameter 2.5 mm to 3 mm) just
distally of the first diagonal branch. The balloon was inflated
under angiographic control to completely occlude the vessel
(Encore™ 26 inflation device, Boston Scientific, Ireland) for
60 min.
Ischemia was followed by two hours of reperfusion. Five
minutes prior to reperfusion, 10 ml of Mirococept (1.5 mg/
ml; corresponding to 0.5 mg/kg [22 nmol/kg]; the dose and
application scheme i.e. one-time application were chosen
according to previous experience and studies [12,15], n=6),
APT154 (non-tailed control, 1.37 mg/ml [equimolar to Mi-
rococept], n=6) or vehicle control (n=6) were slowly
injected intracoronarily, through the catheter tip, into the area
at risk. Thereafter the balloon was deflated to allow for two
hours of reperfusion. Following reperfusion the balloon was
re-inflated, 60 ml Evan's Blue injected intravenously and the
animals sacrificed by intravenous potassium chloride. The
heart was excised for further analysis.
ECG and invasive arterial pressure were recorded through-
out with a Hewlett-Packard CMS patient monitor. Ejection
fraction (EF) was determined angiographically and calculated
using the area-length-method according to Dodge [16].
Fractional shortening (FS) was also determined angiographi-
cally and was assessed in three regions (apical, medial and
basal). The geometric mean of the three regional values was
used for further analyses.
All experimenters were blinded with regard to treatment
regimen. Randomization of the animals into the three groups
was done using a randomization code with a random num-
ber generator (SAS, version 9.1.2, SAS Institute Inc., Cary,
NC, USA), prior to the begin of the series (Mirococept=0,
APT154=1, vehicle controls=2). The 10 ml samples (Miro-
cocept, APT154 or vehicle solution) were prepared accord-
ing to the randomization output and stored at −80 °C until
use. Randomization and sample preparation was performed
by an independent laboratory technician. Prior to pre-medi-
cation of the animals, the corresponding vial was allocated
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the pig). All 18 consecutively enlisted pigs were treated
according to the above-described protocol. No animal was
excluded from or dropped out during the experiment. Sam-
ple size (n=6) was determined in advance, estimated from
previous work [12,17] and experience and not by formal
sample size calculations.
In case of ventricular fibrillation a biphasic defibrillator
(150 J) was used for cardioconversion.
2.3. Infarct size
The area at risk (AAR) was determined by re-occlusion
of the LAD and intravenous injection of 60 ml Evan's
Blue (2% wt/vol solution) at the end of the experiment.
Tissue stained blue was defined as the area not at risk. The
left ventricle was cut perpendicular to the septum into
3 mm slices. Incubation with triphenyl tetrazolium chlo-
ride (TTC, Sigma, pH 7.4, 1% in phosphate buffered
saline) for 20 min at 37 °C was used to stain viable
myocardium (vital ischemic tissue, VIT) from the area at
risk bright red (formazan complex in presence of active
dehydrogenases) whereas infarcted tissue (necrotic ische-
mic tissue, NIT) remains unstained. All three tissue sec-
tions were dissected from each other and weighed. The
area at risk was defined as the sum of necrotic and vital
ischemic tissue. Data were expressed as area at risk as
percent of LVM (AAR/LVM) and necrotic ischemic tissue
as percent of the area at risk (NIT/AAR).
2.4. Complement and coagulation
Venous blood samples were collected (EDTA plasma/
serum), kept on ice until centrifugation (1750 x g for 10 min
at 4 °C) and stored at −80 °C until further analysis.
C3a and C5a were measured by sandwich ELISA as
previously described [18]. In brief, microtiter plates were
coated with a monoclonal antibody (IgG2b) against porcine
C3a/C3a(desArg) or rabbit anti-mouse IgG (Dako, Glostrup,
Denmark) followed by a monoclonal antibody (IgG1) against
porcine C5a. After washing with PBS–Tween, plasma sam-
ples were incubated at a 1:50 (C3a ELISA) or 1:2 (C5a
ELISA) dilution in PBS/Tween/EDTA for 2 h. Biotinylated
monoclonal anti-C3/C3a antibody or rabbit anti-C5a, fol-
lowed by streptavidin-alkaline phosphatase conjugate
(Amersham Pharmacia Biotech, Bucks, UK) and 4-nitrophe-
nyl phosphate substrate (Sigma) were used to detect bound
C3a and C5a (all non-commercial antibodies were obtained
from the Georg-August University, Goettingen — Science-
bridge GmbH, Germany).
Classical pathway complement activity was determined
by standard a CH50 assay with antibody-coated sheep
erythrocytes [19].
Activated partial thromboplastin time (aPTT) was mea-
sured using Dade Actin FS reagent in a standard coagulation
assay as a global parameter for the coagulation system.2.5. Troponin I
Troponin I was measured by liquid suspension array
technique using the Luminex fluorescent bead platform.
Mouse anti-human troponin I (Abcam Ltd, clone 19C7),
biotinylated using the EZ-Link NHS-PEO Solid Phase
Biotinylation Kit mini spin columns from Pierce (Pierce,
Rockford, IL, USA), was used as the detection antibody and
mouse anti-human troponin I, cross-reactive with porcine
troponin I (Abcam Ltd., Cambridge, UK, clone 16A11), was
used as the capture antibody. Covalent coupling of the
capture antibody to the region-specific microspheres was
performed using the Bio-Plex Amine Coupling Kit (Bio-
Rad). Analysis was done with the Bio-Plex system and Bio-
Plex Manager version 4.0 software (Bio-Rad) with five-
parametric curve fitting. Assay conditions were derived from
those of commercial tests.
2.6. Histology and immunostaining
Tissue samples from the area not at risk as well as necrotic
and vital ischemic tissue were fixed in 4% buffered for-
maldehyde, paraffin-embedded, cut into 3 μm sections and
stained with hematoxylin-eosin for histological evaluation.
Neutrophil tissue numbers were determined by myeloper-
oxidase (MPO) staining on additional tissue sections. Anti-
gen-retrieval was performed with target retrieval solution
(Dako, Glostrup. Denmark) and demasking at 96 °C for
30 min. Following peroxidase block (Dako) MPO was de-
tected using a polyclonal antibody to MPO (Dako) and
visualized with a horseradish peroxidase-labeled secondary
antibody and EnVision+ System (Dako). Neutrophil numb-
ers were quantified in 10 randomly selected high-power
viewing fields from the tissue samples of each experiment.
The intravascular/interstitial ratio was calculated for each
section and experiment and averaged for all experiments in
each of the three groups.
For complement and tissue factor detection, 5 μm sec-
tions were cut from all snap frozen tissue samples, air-dried,
acetone fixed, hydrated and labeled using a two-step indirect
immunofluorescence technique. The following antibodies
were used: rabbit anti-human C1q, C3b/c and C4b/c (Dako);
goat anti-human C6 (Quidel, for detection of the membrane
attack complex). Cross-reactivity with the respective por-
cine antigens was verified. Secondary antibodies were goat
anti-rabbit IgG(H+L)-FITC (Southern Biotechnology Asso-
ciated) and rabbit anti-goat Ig-FITC (Dako). Immunohisto-
chemical staining for tissue factor (TF) with polyclonal rabbit
anti-humanTF antibodywas carried out as reported previously
[20].
For every individual experiment four samples per area
(area not at risk, ischemic viable and necrotic areas) were
graded according to the following scoring system: 0: no
staining, 1: minimal focal or diffuse staining, 2: moderately
strong focal or diffuse staining, 3: extensive focal or diffuse
staining.
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tone-fixed cryosections using Cy3-labeled 3E10 antibody
(mouse anti-human sCR1-3 monoclonal antibody, provided
by Inflazyme).
2.7. Quantification of myocyte apoptosis by TUNEL
Myocyte apoptosis was detected on paraffin-embedded
sections in high-power fields by terminal deoxynucleotidyl
transferase-mediated dUTP nick end-labeling (TUNEL,
Chemicon Inc., Millipore, Billerica, MA, USA). TUNEL-
positive nuclei that were not definitively of myocyte origin
were excluded from counting. The extent of apoptosis was
expressed by normalizing the results to the total number of
myocyte nuclei per high-power field.
2.8. Statistics
Data from triphenyl tetrazolium chloride staining (AAR/
LVM in % and NIT/AAR in %, primary endpoint) were
compared between the three groups by use of one-way-ana-
lysis of variance (ANOVA). Results for all other parameters
(secondary endpoints) were compared by use of two-way
repeated-measures ANOVAwith time and treatment as fixed
factors. Subject number was included as random. Effects of
interest were overall between-group differences and interac-
tion between group and time. The assumption of the sphericity
of our data was analyzed by Mauchly's test and corrections
were made where appropriate (Greenhouse-Geisser). In case
of a significant p-value in the overall ANOVAwith respect toFig. 1. Staining for Mirococept using Cy3-labeled 3E10 antibody (mouse anti-h
detected in damaged vessels and myocardium in Mirococept-treated animals. No st
animals. Scale bar: 50 μm.group⁎ time interaction, post-hoc analyses were performed.
Holm's procedure was used in post-hoc pair-wise compar-
isons to control for type I error. For all analyses p-values were
two-sided and differences were considered to be statistically
significant with a p-value of b0.05. SAS Version 9.1.2 (SAS
Institute Inc., Cary, NC, USA) and SPSS Version 12.0.1
(SPSS Inc., Chicago, IL, USA) software were used for all
analyses. Data, unless otherwise specified, are presented as
average±standard deviation in text and figures.
3. Results
3.1. Tissue and plasma levels of Mirococept
Bound Mirococept was found mainly in the area at risk,
both in viable and necrotic ischemic tissue, on the inner
lining of small and large blood vessels and in the myo-
cardium, and to a lesser extent in non-ischemic myocardial
tissue (Fig. 1). Staining for APT154 essentially revealed no
tissue positivity. No staining was observed at distant sites
(lung, kidney, liver). In an ELISA for Mirococept, small
amounts were detected in circulation 5 min after reperfusion
(3.4±0.8 μg/ml). Plasma levels decreased after 1 h and 2 h
reperfusion (1.8±0.5 μg/ml, 0.8±0.2 μg/ml respectively,
results not shown).
3.2. Infarct size
The myocardial area at risk (AAR) as percentage of left
ventricular mass (LVM) was not different in the three groups:uman sCR1-3 monoclonal antibody). Specific deposition of Mirococept is
aining is detected in representative samples from APT154- or vehicle-treated
Fig. 2. Ratio of area at risk (AAR) to left ventricular mass (LVM), as detected by Evan's Blue staining (A). Ratio of necrotic ischemic tissue (NIT) to AAR as
detected by triphenyl tetrazolium chloride (TTC) staining (B). Individual values and means (bars) are shown. Comparable AAR in all groups (p=ns between
groups). NIT as percent of AAR: p=0.0003 (⁎) Mirococept vs. controls, p=0.0001 (⁎⁎) Mirococept vs. APT154, p=0.880 APT154 vs. controls. Representative
pictures of the respective staining are shown as inserts (in A: whole section of left and right ventricle, in B: magnified image of Evan's Blue negative section after
TTC staining). Levels of troponin I as measured in EDTA plasma samples by sandwich immunoassay (C). Results are presented as mean±standard deviation.
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9.4%, in the Mirococept animals, 38.3±6.5% in the APT154
animals, and 36.5±4.8% in the vehicle controls ( p=0.968
Mirococept vs. APT154; p=0.886 Mirococept vs. vehiclecontrols, p=0.900 APT154 vs. vehicle controls). The corres-
ponding wet weights in grams were 33.7±6.7 g, 34.7±8.5 g
and 29.5±3.3 g, respectively. However, infarcted tissue
(necrotic ischemic tissue, NIT) as percentage of AAR was
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42.5±4.0% in the Mirococept treated animals ( pb0.001).
Administration of APT154 did not reduce infarct size,
which, at 60.8±5.1% of the AAR, was not significantly
different to vehicle controls (p=0.880). Wet weights of NIT
were 14.4±3.3 g in the Mirococept animals, 21.0±4.8 g in
the APT154 group, and 18.1±1.6 g in the vehicle controls
(Fig. 2A and B).
3.3. Plasma troponin I
Plasma troponin I increased in all groups following
reperfusion from similar baseline- (average for all groups
6±8 ng/ml) and ischemia-levels to 776±372 ng/ml in theFig. 3. Heart rate (HR, A), mean arterial pressure (MAP, B), left ventricular end-
motility (fractional shortening, FS, E; geometric means of basal, medial and apical v
groups throughout. LVEDP: p=0.033 (⁎) for Mirococept vs. vehicle controls d
ischemia, p=0.081 for Mirococept vs. vehicle controls, p=0.096 for Mirococept
group-time interaction during ischemia, p=0.078 for Mirococept vs. vehicle contro
standard deviations.vehicle controls, 566±246 ng/ml in APT154 animals, and
344±153 ng/ml in Mirococept treated animals after 2 h
reperfusion ( p=0.888 for overall group-time interaction,
Fig. 2C).
3.4. Hemodynamics
Heart rate did not differ significantly amongst the three
groups throughout the experimental procedure (p=0.888 for
overall group-time interaction, Fig. 3A).
Baseline mean arterial pressures (MAP) as well as pres-
sures during the experiments were also not significantly
different in the three groups. (p=0.888 for overall group-
time interaction, Fig. 3B).diastolic pressure (LVEDP, C), ejection fraction (EF, D) and regional wall
alues) recorded throughout the experiments. HR andMAP: p=ns between all
uring reperfusion. EF: p=0.048 for overall group-time interaction during
vs. APT154 during reperfusion. Fractional shortening: p=0.032 for overall
ls, p=0.098 for Mirococept vs. APT154 during reperfusion. Data are mean±
Table 1
Representation of intravascular/interstitial ratio and total number of tissue
neutrophils in myocardial samples
Group ANR VIT NIT
Mirococept 0.84±0.34 (5±1) 1.27±0.35 (10±4)⁎ 0.37±0.08 (16±3)
APTI54 0.80±0.21 (4±1) 1.06±0.26 (10±4)⁎⁎ 0.35±0.06 (14±2)
Vehicle
controls
0.81±0.22 (4±1) 0.77±0.24 (16±4) 0.29±0.07 (14±2)
Four samples per area and experiment were examined and an average
calculated from these. ⁎ denotes p=0.021 Mirococept vs. vehicle controls
(neutrophil ratio) and p=0.040 Mirococept vs. vehicle controls (neutrophil
numbers); ⁎⁎ denotes p=0.043 APT154 vs. vehicle controls (neutrophil
numbers). ANR: area not at risk, VIT: vital ischemic tissue, NIT: necrotic
ischemic tissue.
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and significantly increased in all three groups during ische-
mia (p=0.009 for overall group-time interaction). Following
reperfusion, LVEDP decreased in all groups, most markedly
in the Mirococept treated group. LVEDP was significantly
lower in the Mirococept group as compared to vehicle con-
trols (p=0.033). Other between group differences (Miroco-
cept vs. APT154 and APT154 vs. vehicle controls) were not
significant (Fig. 3C).
Ejection fraction significantly decreased in all three
groups during LAD occlusion from similar baseline values
(overall group-time interaction p=0.048). Recovery during
reperfusion was more rapid in the Mirococept group. Post-
hoc analyses for between group differences showed
p=0.081 for Mirococept vs. vehicle controls, p=0.096
for Mirococept vs. APT154 and p=0.678 for APT154 vs.
vehicle controls (Fig. 3D).
Basal and medial, but particularly apical (not shown
separately) regional wall motility (fractional shortening, FS)
was impaired in all three groups during ischemia as com-
pared to baseline, and only showed some recovery towards
the end of the reperfusion period, with a tendency towards
better recovery in the Mirococept group as compared to
vehicle controls and the APT154 animals (overall group-
time interaction p=0.032, post-hoc analysis: p=0.078 for
Mirococept vs. vehicle controls, p=0.098 for Mirococept
vs. APT154 and p=0.323 for APT154 vs. vehicle controls,
Fig. 3E).
The need for defibrillation for ventricular fibrillation was
not significantly different in the three groups (2 animals per
group).
3.5. Histology and neutrophil numbers
Reperfusion damage was evident in the necrotic myocar-
dium of all three groups, comprising contraction bands and
coagulation necrosis. Gross hemorrhage was observed in two
animals of each group. Microscopic hemorrhagic infarction
was detected in all groups (n=2 for Mirococept and
APT154, n=3 for vehicle controls). Focal minimal signs of
ischemia (wavy fibers) were noted in all three groups in the
viable ischemic tissue. Samples from non-ischemic myocar-
dium showed normal histological findings.
The total numbers and intravascular/interstitial ratios of
neutrophils in tissue samples are shown in Table 1. Miro-
cocept significantly prevented neutrophil extravasation,
particularly in vital ischemic tissue (ratio 1.27±0.35,
p=0.021 vs. vehicle controls). Ratios in the area not at
risk and in necrotic ischemic tissue were not significantly
different between the three groups. Neutrophil numbers
in non-ischemic and necrotic tissue from all three
groups did not differ significantly. However, treatment
with Mirococept significantly reduced MPO positive
cells within the vital ischemic tissue as compared
to sections from APT154 and vehicle control animals
(p=0.031).3.6. Complement deposition and soluble complement
parameters
Fig. 4 summarizes the data of complement deposition
and soluble complement parameters. Samples from all ex-
periments were stained and graded: 0: no staining, 1: mi-
nimal focal or diffuse staining, 2: moderately strong focal
or diffuse staining, 3: extensive focal or diffuse staining.
Normal tissue samples from healthy pigs (not shown) and
from myocardium not at risk served as controls. Mirococept
markedly reduced complement deposition (C1q, C4b/c,
C3b/c, and membrane attack complex) in necrotic ischemic
tissue as compared with vehicle controls and APT154
treated animals. Essentially no, or only minimal, comple-
ment staining was observed in myocardium of healthy pigs
or in myocardium not at risk of all three treatment groups
(Fig. 4A and B).
Levels of the anaphylatoxins C3a and C5a, expressed
as percentage of baseline, did not vary greatly throughout
the experiment and were not significantly different be-
tween the three groups after 2 h reperfusion (p=0.422
Mirococept vs. vehicle controls, p=0.277 Mirococept vs.
APT154, p=0.395 APT154 vs. vehicle controls for C3a;
p=0.317 Mirococept vs. vehicle controls, p=0.162 Miro-
cocept vs. APT154, p=0.243 APT154 vs. vehicle controls
for C5a, Fig. 4C).
CH50 tests were performed to evaluate systemic com-
plement activity of the classical pathway. CH50 values were
calculated as % lysis, where lysis of red blood cells in water
was set to 100%. Baseline CH50 values were not signi-
ficantly different in the groups and values remained largely
unaffected in both the APT154 and vehicle groups. Miro-
cocept significantly inhibited the classical pathway of com-
plement, as apparent CH50 values dropped and remained
significantly lower after 2 h reperfusion (14±2% at 5 min
reperfusion, 25±5% at 2 h reperfusion; p=4.3×10−7 for
overall group-time interaction. Post-hoc analysis at 120 min
reperfusion: p=0.0018 Mirococept vs. vehicle controls, p=
0.0012 Mirococept vs. APT154, p=0.332 APT154 vs. ve-
hicle controls, results not shown).
Fig. 4. Grading for complement tissue deposition of C1q, C3b/c, C4b/c and membrane attack complex (detected as C6), as well as ELISA for C3a and C5a in
plasma. Four samples per area and experiment were graded with respect to intensity for complement staining. Each point represents the average of all evaluations
for one experiment. 0=essentially no staining, 1=minimal focal or diffuse staining, 2=moderately strong focal or diffuse staining 3=extensive diffuse staining.
Results for staining in the necrotic ischemic tissue (NIT) are shown for Mirococept- (black circles), APT164-treated animals (grey circles) as well as vehicle
controls (white circles, A). Representative samples from theNITof all three experiments for complement staining are visualized (B). Scale bar: 50 μm. PlasmaC3a
and C5a levels are presented as a percentage of baseline (set to 100%). Systemic C3a and C5a generation was not influenced by treatment with Mirococept (C).
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Compared to vehicle controls, Mirococept treatment re-
duced vascular TF expression in necrotic ischemic tissue.
Upregulation of TF in the vehicle controls as well as APT154
treated animals within the injured vasculature was associated
with the infarcted areas. Some weak TF staining was noted in
vessels obtained from the area not at risk and vital ischemic
tissue, with no differences between the groups. Minimal
expression of TF was observed within native cardiac vascu-
lature of healthy swine (Fig. 5).Values for activated partial thromboplastin time (aPTT)
did not differ significantly at baseline or any other time
between the groups (p=0.875 for overall group-time
interaction, p=0.698 for overall between group differ-
ences, not shown).
3.8. TUNEL staining
Fig. 6 illustrates TUNEL-positive myocytes at high-power
magnification from representative experimental samples.
Although a large fraction of myocytes were TUNEL-positive
Fig. 5. Staining for pro-coagulant tissue factor in vital, ischemic tissue (VIT) and necrotic, ischemic tissue (NIT) sections. Positivity is revealed as brown staining
(black arrow). Representative sections from each of the three groups are shown. Scale bar: 50 μm.
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cells was significantly greater in samples from vehicle con-
trols (69±8) and from the APT154 (63±7) group as com-
pared to the Mirococept (37±4) treated animals (p=1.0×
10−6 and p=1.6×10−6, respectively). Within the non-ische-
mic and vital ischemic area, the numbers of TUNEL-positive
myocytes were few and not significantly different between
the three groups (not shown).Fig. 6. Terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TU
myocytes stain brown. Representative sections from each of the three groups are sh
100 μm. Mirococept vs. APT154: p=1.6×10−6 (⁎), Mirococept vs. vehicle: p=1.4. Discussion
Our data show that site-specific application of the mem-
brane-targeted recombinant complement inhibitor Miroco-
cept to ischemic myocardium significantly prevented I/R
injury and in part ameliorated cardiac function in the early
reperfusion period. Cardioprotection was associated with
binding of Mirococept to ischemic tissue and was notNEL) of myocardial tissue (necrotic ischemic tissue, NIT). TUNEL-positive
own. Inlay with magnification of two TUNEL-positive myocytes. Scale bar:
0×10−6 (⁎⁎).
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binding form (APT154).
As organs injured following ischemia and reperfusion
locally up-regulate complement [3], it may be advantageous
to target protective agents to the actual site of injury. Indeed,
previous work by Horstick et al. has documented the efficacy
of local, intracoronary C1-inhibitor in reducing myocardial
damage in a porcine infarction model [21]. Furthermore,
although the therapeutic success of systemic complement
inhibition, for example using soluble CR1, has been well
documented [6,22–24], strategies chiefly, but not necessarily
exclusively, targeting the organ locally may provide several
advantages over systemic application. Undesired binding to
non-target organs, particularly excretory organs such as the
kidney, may largely be avoided and lower doses may be
required to achieve the same effect, avoiding complications
potentially associated with systemic complement inhibition.
Indeed, in our study, Mirococept was effective at a dose of
0.5 mg/kg, as compared to studies using soluble CR1 in pigs,
where up to 10 mg/kg were used [25]. However, as the
results reveal, Mirococept's beneficial effect was not entirely
complete for all investigated aspects. Possibly an interme-
diate dose (between 0.5 and 10 mg/kg) may be more
effective for local application strategies. Although such
dosage considerations may be of less importance where
short-term complement inhibition is needed, they may well
prove significant for long-term therapies. Clearly however,
pronounced systemic inflammation in addition to local I/R
injury, such as occurs during cardiopulmonary bypass sur-
gery, may require systemic complement inhibition in addi-
tion to site-targeted cytoprotection. Also, it remains to be
investigated whether concurrent low-dose systemic inhibi-
tion may provide additional benefits.
Strategies to target complement inhibitors to cell mem-
branes have included linking these to sialyl Lewis-x moieties
[26]. Other strategies include taking advantage of the fact that
endothelial damage causes shedding of the glycocalyx [27] to
reveal a pro-inflammatory and pro-coagulant surface. We
previously demonstrated that the complement inhibitor [28–
30] and glycosaminoglycan analog low molecular weight
dextran sulfate selectively binds to endothelial cells denu-
dated of their protective glycocalyx layer in vitro [30] and
protects from I/R injury in acute myocardial infarction in pigs
following intracoronary administration [17]. The current
data with Mirococept confirm the possibility of achieving a
similar degree of protection, albeit using a substance with
different cell membrane-tethering properties.
Unlike the myristoyl-tailed Mirococept, non-tagged
APT154 was not detected in myocardial tissue samples and
did not provide cardioprotection; this, despite infusion of an
equivalent molar dose and local, intracoronary application.
We attribute the failure of APT154 to protect from I/R injury
to the fact that the infused agent was not targeted to bind to the
site of damage and, once systemically in circulation, did not
suffice to offer protection. Results from the CH50 test, which
was used to evaluate systemic complement inhibition, wouldindeed suggest that the APT154 in circulation did not sys-
temically affect complement activity. Results with Miroco-
cept imply that the applied dose not only sufficed to locally
bind to and inhibit tissue complement activation, but also
affected complement activity systemically. This may, in part,
represent an in vitro phenomenon [10], whereby small
amounts of unbound, quasi-surplus Mirococept, added in
vitro to antibody-sensitized sheep erythrocytes, were enough
to bind to the comparatively few erythrocytes and substan-
tially inhibit complement. However, these results may also
reflect a certain amount of true systemic complement inhi-
bition in vivo. Whether this is due to shedding of initially
boundMirococept into the blood stream or represents excess,
unbound Mirococept, washed out of the coronary circulation
without initial local binding to the vasculature, remains to be
investigated. Nonetheless, the peak amounts detected in vivo
suggest that most of the injected Mirococept was bound
locally. Indeed, no staining for Mirococept was detectable in
distant organs (including liver and kidneys).
The mechanism by which Mirococept exerts its cardio-
protective effects may, in part, be deduced from the known
mode of action of native CR1, as Mirococept retains enough
activity of CR1 necessary for breakdown of complexed
complement fragment C3b within C3 convertases [14] and
hence for an inhibitory effect on generation of the anaphy-
latoxins C3a and C5a and the membrane attack complex.
Indeed, all of the complement components studied,
from C1q and C4b/c of the classical complement pathway
to C3b/c, and C6 of the membrane attack complex, were
reduced in myocardial tissue samples from Mirococept-
treated animals. Reduction of anaphylatoxins has been
described in vena cordis magna blood with the use of C1-
inhibitor. Systemic C3a and C5a levels however did not vary
greatly and were not influenced by Mirococept administra-
tion. This may be attributed to the minimal amounts of
systemically-available unbound Mirococept and its largely
restricted local action. C3b and membrane attack complex
are associated with promotion of leukocyte activation via
upregulation of adhesion molecules [31]. Compared to
vehicle controls and APT154, Mirococept significantly
reduced total neutrophil numbers in the viable ischemic
tissue and decreased the extravasation of neutrophils into this
area. sCR1 and sialyl Lewis-x glycosylated sCR1 have been
shown to reduce neutrophil accumulation in a model of
stroke [32]. However, maximal tissue neutrophil accumula-
tion is not observed following only two hours of reperfusion
and non-complement-dependent mechanisms of leukocyte
recruitment may also be of importance in this setting. As a
certain reduction in neutrophil extravasation was also
observed in the APT154 group, it remains to be verified if
Mirococept's protective effects are, at least in part,
attributable to modification of neutrophil extravasation,
particularly in later stages of more pronounced tissue
extravasation.
This endothelial protective effect translated into reduced
tissue factor (TF) expression in Mirococept treated animals,
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While Mirococept does not influence coagulation systemi-
cally (no effect on aPTT), attenuating intravascular throm-
bosis and inflammation by limiting endothelial TF expression
may prove fundamental in reducing I/R damage [33].
Myocardial ischemia has also been shown to induce
apoptosis in animal models and humans [34,35]. Treatment
with Mirococept not only significantly reduced myocardial
necrosis but also I/R-induced apoptosis. This reduction may
be related to the observed reduced terminal complement
complex deposition in the ischemic myocardium, which has
been shown to play an important role not only in I/R-induced
necrosis but also apoptosis [36].
4.1. Limitations
TTC staining, though under debate for determining in-
farct size following short reperfusion times, was used here,
as its staining validity for 120 min reperfusion in pigs has
previously been confirmed, where viable TTC positive islets
within TTC negative necrotic tissue correlated with electron
microscopy findings [37]. Isoflurane, known to have a pre-
conditioning effect [38], may have contributed to a certain
degree of cardioprotection. However, this effect would be
equal in all groups and would not explain the benefits
observed with the use of Mirococept.
Although Mirococept provides protection in the critical
initial phase of reperfusion, further studies are required to
validate whether a one-time application of Mirococept offers
extended protection from complement-mediated damage. In
particular, functional analysis, including regional wall moti-
lity, would also need to be evaluated at a later stage, as
myocardial stunning, a likely significant finding in all groups
in the early post-reperfusion phase, may hamper initial in-
vestigations and skew early results.
5. Conclusions
In summary, we have demonstrated the feasibility of
modifying the local pro-inflammatory and pro-coagulant en-
vironment encountered following regional myocardial ische-
mia and reperfusion by targeting a complement regulatory
protein to the site of injury. This protection was associated
with a single dose application of amolecule previously proven
safe for use in humans. The concept of targeted cytoprotection
of ischemic tissue pre-reperfusion using substances such as
Mirococept, may offer an attractive therapeutic option in
treating reperfusion injury and warrants further investigation.
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